Matthew Ingham

1.6k total citations · 1 hit paper
50 papers, 829 citations indexed

About

Matthew Ingham is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Matthew Ingham has authored 50 papers receiving a total of 829 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pulmonary and Respiratory Medicine, 31 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in Matthew Ingham's work include Sarcoma Diagnosis and Treatment (25 papers), CAR-T cell therapy research (12 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Matthew Ingham is often cited by papers focused on Sarcoma Diagnosis and Treatment (25 papers), CAR-T cell therapy research (12 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Matthew Ingham collaborates with scholars based in United States, Canada and United Kingdom. Matthew Ingham's co-authors include Gary K. Schwartz, Seth M. Pollack, Thomas W. Dubensky, Robert H.I. Andtbacka, Jason J. Luke, Sarah M. McWhirter, Jincheng Wu, Thomas Müller, Matthew B. Spraker and Nancy Lewis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Matthew Ingham

46 papers receiving 816 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

2021 240 citations Funda Meric‐Bernstam, Randy F. Sweis et al. Clinical Cancer Research profile →

Peers

Matthew Ingham

ONCOL

PRM

IMMUN

Man Jiang China

Huihua Zhang China

Qingyang Feng China

Irene Vanni Italy

Samuel J. Vidal United States

Mengting Liao China

Sujie Zhang China

Alex Chehrazi‐Raffle United States

Anna Maria Granato Italy

Man Jiang China

Matthew Ingham

389 ×1.1

ONCOL

257 ×0.8

229 ×0.8

PRM

256 ×0.9

IMMUN

132 ×1.0

Citations per year, relative to Matthew Ingham Matthew Ingham (= 1×) peers Man Jiang

Countries citing papers authored by Matthew Ingham

Since Specialization

Citations

This map shows the geographic impact of Matthew Ingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Ingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Ingham more than expected).

Fields of papers citing papers by Matthew Ingham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Ingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Ingham. The network helps show where Matthew Ingham may publish in the future.

Co-authorship network of co-authors of Matthew Ingham

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Ingham. A scholar is included among the top collaborators of Matthew Ingham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Ingham. Matthew Ingham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Harrington, Kevin J., Stéphane Champiat, Joshua Brody, et al.. (2025). Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research. 31(16). 3400–3411. 10 indexed citations

Siddiqui, Bilal A., Benedito A. Carneiro, Mark N. Stein, et al.. (2025). A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 43(5_suppl). 1 indexed citations

Kelly, William Kevin, Sandy Srinivas, Joseph Maly, et al.. (2025). Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 43(5_suppl). 1 indexed citations

Tine, Brian A. Van, Matthew Ingham, Steven Attia, et al.. (2024). Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma. Journal of Clinical Oncology. 42(20). 2404–2414. 3 indexed citations

Ingham, Matthew, Li Chen, Biswajit Das, et al.. (2024). Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS).. Journal of Clinical Oncology. 42(16_suppl). 11526–11526. 3 indexed citations

Gao, Lan, Diksha Kaushik, Brian A. Van Tine, et al.. (2023). Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma. Clinical and Translational Science. 17(2). 1 indexed citations

Bose, Sminu, et al.. (2023). Therapeutic advances in leiomyosarcoma. Frontiers in Oncology. 13. 1149106–1149106. 20 indexed citations

Bose, Sminu, Shing M. Lee, Brian A. Van Tine, et al.. (2023). A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.. Journal of Clinical Oncology. 41(16_suppl). 11565–11565. 1 indexed citations

Meyer, Christian F., Matthew Ingham, James Hu, et al.. (2023). Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.. Journal of Clinical Oncology. 41(16_suppl). 11568–11568. 3 indexed citations

10.

Bose, Sminu, et al.. (2022). CDK4/6 Inhibition With Anti–PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD–1 Alone. JCO Precision Oncology. 6(6). e2100550–e2100550. 2 indexed citations

11.

Ingham, Matthew, Shing M. Lee, Brian A. Van Tine, et al.. (2022). A Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma. Clinical Cancer Research. 29(6). 1031–1039. 8 indexed citations

12.

Kasper, Bernd, Lorenzo D’Ambrosio, Elizabeth J. Davis, et al.. (2022). What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?. Current Treatment Options in Oncology. 23(3). 439–449. 6 indexed citations

13.

Goldstein, Jonathan, Sepideh Besharati, Mary Salvatore, et al.. (2022). A 52-Year-Old Man With Chest Pain and Dyspnea. CHEST Journal. 162(5). e259–e264. 1 indexed citations

14.

Tine, Brian Andrew Van, Matthew Ingham, Steven Attia, et al.. (2022). A phase 1b study of unesbulin (PTC596) plus dacarbazine for the treatment of patients with locally recurrent, unresectable, or metastatic relapsed/refractory leiomyosarcoma.. Journal of Clinical Oncology. 40(16_suppl). 11507–11507. 6 indexed citations

15.

Bose, Sminu, Matthew Ingham, Li Chen, et al.. (2022). Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.. Journal of Clinical Oncology. 40(16_suppl). 11509–11509. 5 indexed citations

16.

Meric‐Bernstam, Funda, Randy F. Sweis, F. Stephen Hodi, et al.. (2021). Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research. 28(4). 677–688. 240 indexed citations breakdown →

17.

Sheikh, Tahir, Xiao Chen, Xinjing Xu, et al.. (2021). Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors. Molecular Cancer Therapeutics. 20(12). 2362–2371. 15 indexed citations

18.

Ingham, Matthew, James Hu, Giles F. Whalen, et al.. (2021). Early results of intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas.. Journal of Clinical Oncology. 39(15_suppl). 11557–11557. 3 indexed citations

19.

Schutt, Charles R., Hua Sun, Yvonne M. Saenger, et al.. (2021). Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma. Oncotarget. 12(6). 534–548. 5 indexed citations

20.

Drake, Charles G., Melissa L. Johnson, Alexander I. Spira, et al.. (2020). Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies.. Journal of Clinical Oncology. 38(15_suppl). 3137–3137. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact